Table 1

Clinical characteristics of the patients at baseline and at year 1a
Characteristics Baseline Year 1
Male sex, n (%) 67 (92%)
Age, years 58 (49 to 65)
Pacific ethnicity, n (%) 25 (34%)
Māori ethnicity, n (%) 18 (25%)
European and other ethnicities, n (%) 30 (41%)
Gout disease duration, years 23 (16 to 28)
Flare frequency (in the preceding three months) 0 (0 to 2) 0 (0 to 2)
Allopurinol use, n (%) 62 (85%) 62 (85%)
Allopurinol dose (n = 62), mg/day 300 (200 to 300) 300 (200 to 300)
Colchicine use, n (%) 33 (45%) 32 (44%)
Nonsteroidal anti-inflammatory drug use, n (%) 46 (63%) 44 (60%)
Prednisone use, n (%) 11 (15%) 12 (16%)
Health assessment questionnaire II score 0.2 (0 to 0.55) 0.15 (0 to 0.58)
Swollen joint count 0 (0 to 0) 0 (0 to 0)
Tender joint count 0 (0 to 1) 0 (0 to 1)
Number of subcutaneous tophi 3 (2 to 9) 3.5 (2 to 8)
Serum creatinine, μmol/L 99 (84 to 112.5) 96 (81 to 112)
C-reactive protein, mg/L 2.4 (1 to 5) 2.1 (1 to 6)
Serum urate, mmol/L 0.36 (0.18 to 0.46) 0.37 (0.32 to 0.46)
Serum urate <0.36 mmol/L, n (%) 34 (47%) 29 (40%)
Serum urate <0.36 mmol/L at both time points, n (%) 21 (29%)

aUnless otherwise specified, data are presented as medians (IQRs).

Rajan et al.

Rajan et al. Arthritis Research & Therapy 2013 15:R160   doi:10.1186/ar4343

Open Data